SCHEMBL681237

SCHEMBL681237

CC(=O)C(N)(N)CCC(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.56
CYP1A2 P05177 2/20 0.56
THRB P10828 2/20 0.56
KMT2A Q03164 2/20 0.56
MEN1 O00255 1/20 0.56
LMNA P02545 5/20 0.42
SLC15A2 Q16348 1/20 0.42
NAALAD2 Q9Y3Q0 1/20 0.39
EGLN1 Q9GZT9 2/20 0.38
ALKBH5 Q6P6C2 1/20 0.38
SUCNR1 Q9BXA5 1/20 0.38
HDAC3 O15379 2/20 0.38
HDAC1 Q13547 2/20 0.38
HDAC2 Q92769 2/20 0.38
HDAC8 Q9BY41 2/20 0.38
FFAR3 O14843 1/20 0.38
GABRP O00591 3/20 0.36
GABRD O14764 3/20 0.36
GABRA1 P14867 3/20 0.36
GABRB1 P18505 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL497168 0.79 THRB (0.54) ALDH1A1CYP1A2THRBKMT2AMEN1
Hydrochloric Acid SCHEMBL28548595 0.77 THRB (0.52) ALDH1A1CYP1A2THRBKMT2AMEN1
SCHEMBL11037692 0.76 ALDH1A1 (0.52) ALDH1A1CYP1A2THRBKMT2AMEN1
SCHEMBL28500432 0.76 ALDH1A1 (0.52) ALDH1A1CYP1A2THRBKMT2AMEN1
SCHEMBL1406211 0.74 LMNA (0.46) ALDH1A1CYP1A2THRBKMT2AMEN1
SCHEMBL11620113 0.74 LMNA (0.46) ALDH1A1CYP1A2THRBKMT2AMEN1
SCHEMBL9586044 0.74 CYP1A2 (0.74) ALDH1A1CYP1A2THRBKMT2AMEN1
SCHEMBL1933286 0.74
SCHEMBL1521278 0.74 HMGCR (0.43) ALDH1A1CYP1A2THRBKMT2AMEN1
SCHEMBL2825360 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3558287-A2 N-ACETYLDIAMINOBUTYRIC ACID-CONTAINING COMPOSITION Bitop AG (DE) 2019-10-30 EP claimed
CN-114806974-B Salmonella strain and application thereof 中国科学院微生物研究所 2023-08-08 CN disclosed
CN-112501102-B Escherichia coli recombinant bacterium for efficiently producing tetrahydropyrimidine 江南大学 2022-10-11 CN disclosed
CN-114806974-A Halomonas strain and application thereof 中国科学院微生物研究所 2022-07-29 CN disclosed
EP-2970511-B1 INSULIN-INCRETIN CONJUGATES UNIV INDIANA RES & TECH CORP (US) 2020-09-30 EP disclosed
US-10730923-B2 Glucagon/GLP-1 receptor co-agonists INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2020-08-04 US disclosed
US-10696726-B2 Insulin-incretin conjugates INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2020-06-30 US disclosed
US-10683334-B2 Aqueously soluble and chemically stable glucagon peptides INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2020-06-16 US disclosed
EP-3206710-B1 INCRETIN-INSULIN CONJUGATES UNIV INDIANA RES & TECH CORP (US) 2020-05-06 EP disclosed
US-20200030214-A1 USE OF COMPATIBLE SOLUTES MERCK PATENT GMBH (DE) 2020-01-30 US disclosed
US-20100316586-A1 STYLING AGENT FOR KERATIN FIBERS HENKEL AG & CO. KGAA (DE) 2010-12-16 US disclosed
WO-2010071807-A1 AMIDE BASED GLUCAGON SUPERFAMILY PEPTIDE PRODRUGS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2010-06-24 WO disclosed
WO-2010011439-A2 GIP-BASED MIXED AGONISTS FOR TREATMENT OF METABOLIC DISORDERS AND OBESITY INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2010-01-28 WO disclosed
WO-2009155258-A2 GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2009-12-23 WO disclosed
WO-2009155257-A1 GLUCAGON ANALOGS EXHIBITING ENHANCED SOLUBILITY AND STABILITY PHYSIOLOGICAL PH BUFFERS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2009-12-23 WO disclosed
EP-2057185-A1 POLYMYXIN DERIVATIVES AND USES THEREOF Northern Antibiotics Oy (FI) 2009-05-13 EP disclosed
WO-2008017734-A1 POLYMYXIN DERIVATIVES AND USES THEREOF NORTHERN ANTIBIOTICS OY (FI) 2008-02-14 WO disclosed
CN-1303991-C Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivative process for preparing the same WARNER LAMBERT CO (US) 2007-03-14 CN disclosed
US-20050201955-A1 Use of compatible solutes for inhibiting the release of ceramides SUSONITY Commercial GmbH (DE) 2005-09-15 US disclosed
CN-1301155-A Stable pharmaceutical formulation of gamma-aminobutyric acid derivatives and process for preparing the same WARNER LAMBERT CO (US) 2001-06-27 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050201955-A1 Use of compatible solutes for inhibiting the release of ceramides CERT1, UGCG, CERS2 ALDH1A1 3836/4885CYP1A2 4709/4885THRB 4877/4885
US-20200030214-A1 USE OF COMPATIBLE SOLUTES SLC9A5, SLC9A1, SLC9A3 ALDH1A1 1133/4885CYP1A2 4075/4885THRB 4881/4885
US-10730923-B2 Glucagon/GLP-1 receptor co-agonists GLP1R, GCGR, GIPR ALDH1A1 4327/4885CYP1A2 3113/4885THRB 70/4885
US-10696726-B2 Insulin-incretin conjugates GLP1R, IAPP, GIPR ALDH1A1 3209/4885CYP1A2 3053/4885THRB 163/4885
US-10683334-B2 Aqueously soluble and chemically stable glucagon peptides IAPP, GLP1R, GCG ALDH1A1 4258/4885CYP1A2 3698/4885THRB 177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.